QL1706 Plus Olaparib
Phase 2Small molecule
QL1706 Plus Olaparib is one of 83 small molecule programs targeting Triple-Negative Breast Cancer. It is currently in Phase 2.
3
Indications
4
Total Trials
4
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
702 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1QL1706 Plus Olaparib
TTianjin Medical University Cancer Institute and Hospital
Phase 2
Recombinant Human Endostatin
PPeking University Third Hospital
Preclinical
Tianeptine
PfizerPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Naltrexone/bupropion
Novo NordiskPreclinical
Sertraline ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Perflutren Lipid Microsphere
IImaRx Therapeutics
Preclinical
Ibrance
PfizerPreclinical
QBX258
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chemotherapy1 trial
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
Recruiting·—·Phase 2·NCT07330596·96 enrolled
Triple-Negative Breast Cancer1 trial
Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast Cancer
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07005583·46 enrolled
Endometrial Adenocarcinoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QL1706 Plus Olaparib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details